Intelligence Platform

Patents

Browse 763 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 11807853

Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and

The Board of Regents of the University of Texas System · Granted Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11793816

Methods for enhancing cytotoxic cancer therapy through inhibition of ATG4B

Northwestern University · Granted Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11793806

Pyruvate kinase activators for use in therapy

Agios Pharmaceuticals, Inc. · Granted Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11793825

Biomarkers for predicting responsiveness to decitabine therapy

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11786500

Glutaminase inhibitor therapy

The Board of Regents of the University of Texas System · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11786542

Methods for enhancing cytotoxic cancer therapy through modulation of purine biosynthesis p

Northwestern University · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11786503

Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity

Auransa Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11779601

Diagnostic methods for T cell therapy

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11781156

Plakophillin-2 gene therapy methods and compositions

Tenaya Therapeutics, Inc. · Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11779660

Viral vectors for cancer therapy

Krystal Biotech, Inc. · Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11759531

Gene therapy vectors for treating heart disease

Tenaya Therapeutics, Inc. · Granted Tue Sep 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11746152

Methods of cancer treatment and therapy using a combination of antibodies that bind glycos

The Board of Regents of the University of Texas System · Granted Tue Sep 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11730828

Gene therapy for haploinsufficiency

The Regents of the University of California · Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11723922

CXCR6-transduced T cells for targeted tumor therapy

Ludwig-Maximilians-Universitat Munchen · Granted Tue Aug 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11723929

Methods of improving cell-based therapy

The Regents of the University of California · Granted Tue Aug 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11723923

Methods of preparing T cells for T cell therapy

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11707536

Viral vectors encoding recombinant FVIII variants with increased expression for gene thera

Takeda Pharmaceutical Company Limited · Granted Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11699503

Methods of identifying and treating patient populations amenable to cancer immunotherapy

The Regents of the University of California · Granted Tue Jul 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11690837

Methods of improving cell-based therapy

The Regents of the University of California · Granted Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11680244

Method for generating human dendritic cells for immunotherapy

The Regents of the University of California · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11679103

Multi-targeting agents for Alzheimer's disease therapy

The Regents of the University of California · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11666574

Combination therapy involving diaryl macrocyclic compounds

TURNING POINT THERAPEUTICS, INC. · Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11660330

Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

VACCINEX, INC. · Granted Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11654145

Combination therapy involving diaryl macrocyclic compounds

TURNING POINT THERAPEUTICS, INC. · Granted Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted